You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
石药(01093.HK)蔡东晨:带量采购牵动市场竞争变革 药企唯有创新图存
阿思达克 10-30 16:16

据《中国经营报》近日报道,石药集团(01093.HK)董事局主席蔡东晨认为,今年9月以来在国家医保局等部门指导下,参与药品带量采购扩围的25个省份和新疆生产建设兵团在上海开展联合招采,产生了拟中选结果。按照规则,联盟采购的25个品种,将由入选的3家企业瓜分全国70%的市场。石药集团出产的75mg规格的氯(口比)格雷药品入选。

蔡东晨表示,带量采购牵动的医药市场竞争规则的变革中,仿制药生产企业面临行业整合机遇。制药企业要生存,就要创新、研发,在创新中求生存。

他指,近年来,国家在医药、医保、医疗三个维度,供给侧和需求侧两个方向进行了深度改革,医药产业趋势发生变化。医药市场的竞争规则和竞争格局逐渐变化,辅助用药、仿制药整体份额面临压缩,创新药整体份额逐步提升。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account